<clinical_study>
<study_id>
<org_name>
  BioMarinPharm
</org_name>
<org_full_name>
  BioMarin Pharmaceutical
</org_full_name>
<org_study_id>
  ASB-008
</org_study_id>
<nct_id>
  NCT00299000
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  BioMarin Pharmaceutical
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Celeste Decker, MD
</name_title>
<organization>
  BioMarin Pharmaceutical Inc.
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
<has_dmc>
  No
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  The primary objective of the study was to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
  The secondary objective of the study was to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.
  The safety objective of the study was to evaluate the safety of two dose levels of Naglazyme in infants under the age of one year who have MPS VI.
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2011-07 
</date>
</status_block>
<start_date>
<date>
  2006-05
</date>
</start_date>
<last_follow_up_date
 type="Actual"
>
<date>
  2009-04
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
  2009-04
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Prevention
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Change in Height
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Change in Weight
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
  Change in Haed Circumference
</measure>
<time_frame>
  52 weeks
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Change in Urinary Glycosaminoglycan Levels
</measure>
<time_frame>
  minimum 52 weeks of dosing
</time_frame>
<description>
<textblock>
  Change in urinary GAG levels was calculated from baseline to week 52 of treatment.
</textblock>
</description>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  4
</enrollment>
<condition>
  Mucopolysaccharidosis VI
</condition>
<condition>
  Maroteaux-Lamy Syndrome
</condition>
<arm_group>
<arm_group_label>
  Naglazyme, 1.0 mg/kg
</arm_group_label>
<arm_type>
  Other
</arm_type>
<description>
<textblock>
  Dose comparison
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  Naglazyme, 2.0 mg/kg
</arm_group_label>
<arm_type>
  Other
</arm_type>
<description>
<textblock>
  Dose Comparison
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Naglazyme
</primary_name>
<description>
<textblock>
  Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
</textblock>
</description>
<arm_group_label>
  Naglazyme, 1.0 mg/kg
</arm_group_label>
<arm_group_label>
  Naglazyme, 2.0 mg/kg
</arm_group_label>
<other_name>
  recombinant human N-acetylgalactosamine 4-sulfatase
</other_name>
<other_name>
  rh-arylsulfatase B
</other_name>
<other_name>
  rhASB
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Signed informed consent by a parent or legal guardian 
 
    - Parent or legal guardian willing and able to comply with all study procedures
 
    - Equal to or greater than 36 weeks estimated gestational age by physical exam at birth
 
    - Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory
 
    - Is less than one year of age
 
    - Has no evidence of skeletal dysplasia based on physical exam
 
 
 
  Exclusion Criteria:
    - Parent of legal guardian perceived to be unreliable or unavailable for study participation
 
    - Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
 
    - Has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation)
 
    - Any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study
 
    - Has known hypersensitivity to Naglazyme
 
    - Has previously received Naglazyme
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
</minimum_age>
<maximum_age>
  1 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Celeste Decker, MD
</name>
<affiliation>
<agency>
  BioMarin Pharmaceutical Inc
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Linda A Scott, RN, BA
</name>
<phone>
  415-506-6700
</phone>
<phone_ext>
</phone_ext>
<email>
  lscott@bmrn.com
</email>
</contact>
<location>
<facility>
<name>
  Children&apos;s Hospital Oakland
</name>
<address>
<city>
  Oakland
</city>
<state>
  California
</state>
<zip>
  94609
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  Paul Harmatz, M.D.
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Paul Harmatz MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Children&apos;s Hospital Los Angeles
</name>
<address>
<city>
  Los Angeles
</city>
<state>
  California
</state>
<zip>
  90027
</zip>
<country>
  United States
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Linda Randolph, BS, MD, FA
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital Femme Mere Enfant Centre
</name>
<address>
<city>
  Lyon
</city>
<state>
</state>
<zip>
  69677
</zip>
<country>
  France
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Natalie Guffon, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
  Hospital PediAtrico de Coimbra
</name>
<address>
<city>
  Coimbra
</city>
<state>
</state>
<zip>
  3000-076
</zip>
<country>
  Portugal
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<role>
  Principal Investigator
</role>
<name>
  Paula Garcia, MD
</name>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  BioMarin Pharmaceutical Inc Website
</textblock>
</annotation>
<url>
  http://www.BRMN.com
</url>
</see_also>
<initial_release_date>
  2006-03-02
</initial_release_date>
<last_release_date>
2011-07-19 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
  2010-05-07
</init_results_release_date>
<clinical_result>
<baseline>
<baselinemeasures>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &lt;=18 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Between 18 and 65 years
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  &gt;=65 years
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
Age  Categorical 
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<dispersionspread>
  4.31
</dispersionspread>
<parametervalue>
  9.23
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<dispersionspread>
  3.89
</dispersionspread>
<parametervalue>
  6.05
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<dispersionspread>
  0.42
</dispersionspread>
<parametervalue>
  12.4
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<title>
Age Continuous 
</title>
<unitofmeasure>
  months
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Female
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  4
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Male
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Gender, Male/Female
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  White, non-Hispanic
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Hispanic/Latino
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Other
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Number
</parametertype>
<title>
  Race/Ethnicity, Customized
</title>
<unitofmeasure>
  participants
</unitofmeasure>
<othertitle>
</othertitle>
</baselinemeasure>
<baselinemeasure>
<dispersiontype>
  Not Applicable
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  United States
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  France
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  Baseline-TotalBaselineRptGroup
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.1
</reportinggroupid>
<parametervalue>
  0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  Baseline-BaselineRptGroup.4
</reportinggroupid>
<parametervalue>
  1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Portugal
</title>
</measurecategory>
</measurecategories>
<parametertype>
  Number
</parametertype>
<title>
  Region of Enrollment
</title>
<unitofmeasure>
  participants
</unitofmeasure>
</baselinemeasure>
</baselinemeasures>
<baselinereportinggroups>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</baselinereportinggroup>
<baselinereportinggroup
 id="Baseline-BaselineRptGroup.4"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</baselinereportinggroup>
</baselinereportinggroups>
<totalbaselinereportinggroup
 id="Baseline-TotalBaselineRptGroup"
>
<subjectsanalyzed>
  4
</subjectsanalyzed>
<title>
  Total
</title>
</totalbaselinereportinggroup>
</baseline>
<certainagreement>
<otherdetails>
<textblock>
  The first publication of the results shall be made by the Sponsor in a joint publication. If such a multicenter publication is not submitted within 12 months after conclusion of the study, the PI may publish the results from site individually, subject however to comply with the other terms of the agreement.
</textblock>
</otherdetails>
<pisponsoremployee>
  No
</pisponsoremployee>
<restrictiontype>
  OTHER
</restrictiontype>
<restrictiveagreement>
  Yes
</restrictiveagreement>
</certainagreement>
<lastupdatetimestamp>
2011-07-19T12:29:43-04:00 
</lastupdatetimestamp>
<limitationsandcaveats>
<description>
<textblock>
  Given the small number of patients (4) represented in this study, the outcomes observed in this study may not reflect or predict outcomes observed by physicians in clinical practice.
</textblock>
</description>
</limitationsandcaveats>
<outcomemeasures>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  86.32
</dispersionspread>
<parametervalue>
  1041.87
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  142.34
</dispersionspread>
<parametervalue>
  698.95
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Baseline
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  54.38
</dispersionspread>
<parametervalue>
  261.15
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  42.43
</dispersionspread>
<parametervalue>
  178.10
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  140.69
</dispersionspread>
<parametervalue>
  -780.72
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.3-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  99.91
</dispersionspread>
<parametervalue>
  -520.85
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change from Baseline to Week 52
</title>
</measurecategory>
</measurecategories>
<measuredescription>
<textblock>
  Change in urinary GAG levels was calculated from baseline to week 52 of treatment.
</textblock>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  minimum 52 weeks of dosing
</timeframe>
<title>
  Change in Urinary Glycosaminoglycan Levels
</title>
<unitofmeasure>
  ug/mg creatinine
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Secondary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.3-OutcomeRptGroup.4"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intention to treat.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  5.1
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  67.3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  1.8
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  80.3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Height at baseline
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  1.8
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  81.9
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  5.2
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  91.3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Height at week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  6.9
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  14.6
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.7-OutcomeRptGroup.4
</reportinggroupid>
<dispersionspread>
  7.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  11.0
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change in height
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  52 weeks
</timeframe>
<title>
  Change in Height
</title>
<unitofmeasure>
  centimeters
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 1.0 mg/kg
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.7-OutcomeRptGroup.4"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 2.0 mg/kg
</title>
<numunitsanalyzed>
</numunitsanalyzed>
</outcomereportinggroup>
</outcomereportinggroups>
<populationanalysisdescription>
<textblock>
  Intention to treat.
</textblock>
</populationanalysisdescription>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  .3
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  7.1
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  .6
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  10.2
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  weight at baseline
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  .3
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  11.3
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  1.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  13.3
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  weight at week 52
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  .6
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  4.2
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.8-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  1.6
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  3.1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  change in weight
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  52 weeks
</timeframe>
<title>
  Change in Weight
</title>
<unitofmeasure>
  kilograms
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.8-OutcomeRptGroup.2"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
<outcomemeasure>
<dispersiontype>
  Standard Deviation
</dispersiontype>
<measurecategories>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  3.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  43.5
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  .5
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  49.1
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  head circumference at baseline
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  1.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  48.5
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  .8
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  51.8
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  head circumference at 52 weeks
</title>
</measurecategory>
<measurecategory>
<reportedvalues>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.1
</reportinggroupid>
<dispersionspread>
  4.0
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  5.0
</parametervalue>
</reportedvalue>
<reportedvalue>
<reportinggroupid>
  OutcomeMeasure.9-OutcomeRptGroup.2
</reportinggroupid>
<dispersionspread>
  1.3
</dispersionspread>
<nacomment>
</nacomment>
<parametervalue>
  2.7
</parametervalue>
</reportedvalue>
</reportedvalues>
<title>
  Change in head circumference
</title>
</measurecategory>
</measurecategories>
<measuredescription>
</measuredescription>
<parametertype>
  Mean
</parametertype>
<timeframe>
  52 weeks
</timeframe>
<title>
  Change in Haed Circumference
</title>
<unitofmeasure>
  centimeter
</unitofmeasure>
<anticipatedresultpostingdate>
<month>
</month>
<year>
</year>
</anticipatedresultpostingdate>
<measuretype>
  Primary
</measuretype>
<outcomemeasureanalyses>
</outcomemeasureanalyses>
<outcomereportinggroups>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</outcomereportinggroup>
<outcomereportinggroup
 id="OutcomeMeasure.9-OutcomeRptGroup.2"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<subjectsanalyzed>
  2
</subjectsanalyzed>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</outcomereportinggroup>
</outcomereportinggroups>
<reportingstatus>
  Posted
</reportingstatus>
<safetyissue>
  No
</safetyissue>
<typeunitsanalyzed>
</typeunitsanalyzed>
</outcomemeasure>
</outcomemeasures>
<participantflow>
<participantflowgroups>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</flowgroup>
<flowgroup
 id="ParticipantFlow-ParticipantFlowGroup.4"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</flowgroup>
</participantflowgroups>
<periods>
<period>
<completedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  2
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.4
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  2
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</completedmilestone>
<dropwithdrawreasons>
</dropwithdrawreasons>
<milestones>
</milestones>
<otherparticipantflowdetails>
<otherdetail>
<numbernotcompleted>
  0
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
</otherdetail>
<otherdetail>
<numbernotcompleted>
  0
</numbernotcompleted>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.4
</reportinggroupid>
</otherdetail>
</otherparticipantflowdetails>
<startedmilestone>
<milestoneachievements>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.1
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  2
</subjectsachieve>
</milestoneachievement>
<milestoneachievement>
<reportinggroupid>
  ParticipantFlow-ParticipantFlowGroup.4
</reportinggroupid>
<comment>
</comment>
<subjectsachieve>
  2
</subjectsachieve>
</milestoneachievement>
</milestoneachievements>
</startedmilestone>
<title>
  Overall Study
</title>
</period>
</periods>
<preassignmentdescription>
</preassignmentdescription>
<recruitmentdetails>
<textblock>
  Global study sites were hospitals.
 
  First Enrollment:  08MAY2006
 
  Last Dose: 30APR2009
</textblock>
</recruitmentdetails>
</participantflow>
<pointofcontact>
<email>
  medinfo@bmrn.com
</email>
<organizationname>
  BioMarin Pharmaceutical Inc.
</organizationname>
<phoneextension>
</phoneextension>
<phonenumber>
  800-983-4587
</phonenumber>
<title>
  Medical Information Services
</title>
</pointofcontact>
<recordstatus>
  RELEASED
</recordstatus>
<reportedevents>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<frequencyreportingthreshold>
  5
</frequencyreportingthreshold>
<frequentadverseevents>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Diarrhea
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  4
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Ear infection
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  15
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Nasal congestion
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  8
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  31
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  General disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Pyrexia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Rhinitis
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Umbilical hernia
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  9
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Upper respiratory tract infections
</term>
</frequentevent>
<frequentevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  2
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Vomiting
</term>
</frequentevent>
</frequentadverseevents>
<interventiongroups>
<interventiongroup
 id="ReportedEvents-InterventionGroup.1"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<numsubjectsfrequentevents>
  2
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  2
</numsubjectsseriousevents>
<partatriskfrequentevents>
  2
</partatriskfrequentevents>
<partatriskseriousevents>
  2
</partatriskseriousevents>
<title>
  Naglazyme, 1.0 mg/kg
</title>
</interventiongroup>
<interventiongroup
 id="ReportedEvents-InterventionGroup.4"
>
<description>
<textblock>
  weekly infusions for minimum of 52 weeks
</textblock>
</description>
<numsubjectsfrequentevents>
  2
</numsubjectsfrequentevents>
<numsubjectsseriousevents>
  2
</numsubjectsseriousevents>
<partatriskfrequentevents>
  2
</partatriskfrequentevents>
<partatriskseriousevents>
  2
</partatriskseriousevents>
<title>
  Naglazyme, 2.0 mg/kg
</title>
</interventiongroup>
</interventiongroups>
<notes>
</notes>
<seriousadverseevents>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  2
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Adenoidal hypertrophy
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Surgical and medical procedures
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Cast application
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Nervous system disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Febrile convulsion
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Pneumonia
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Vascular disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Poor venous access
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Respiratory, thoracic and mediastinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Respiratory distress
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  3
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Musculoskeletal and connective tissue disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Scoliosis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Infections and infestations
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Tonsillitis
</term>
</seriousevent>
<seriousevent>
<adverseeventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.1
</reportinggroupid>
<numevents>
  0
</numevents>
<numsubjectsaffected>
  0
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
<eventstats>
<reportinggroupid>
  ReportedEvents-InterventionGroup.4
</reportinggroupid>
<numevents>
  1
</numevents>
<numsubjectsaffected>
  1
</numsubjectsaffected>
<numsubjects>
  2
</numsubjects>
</eventstats>
</adverseeventstats>
<assessmenttype>
  Systematic Assessment
</assessmenttype>
<notes>
</notes>
<organsystemname>
  Gastrointestinal disorders
</organsystemname>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<term>
  Umbilical hernia
</term>
</seriousevent>
</seriousadverseevents>
<sourcevocabulary>
  MedDRA (12.0)
</sourcevocabulary>
<timeframe>
  All patients received weekly infusions of Nagalzyme for a minimum of 52 weeks.  The range in time of exposure to Naglazyme for the duration of the study was 52.9 to 153.30 weeks.
</timeframe>
</reportedevents>
</clinical_result>
</clinical_study>
